Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

Inclusion Criteria: * Seropositive for herpes simplex virus type 2 (HSV-2) * Clinically active genital herpes defined as a history of 1-9 episodes per year for at least 1 year prior to screening or 1 year prior to beginning suppressive therapy. * Willing to either use an effective method of contraception or abstain from sexual intercourse throughout the 48-week study period. * If female of childbearing potential, have a negative serum pregnancy test. * Agree to not receive any other investigational drugs while enrolled in this study. * The above criteria must be met before participants are allowed to enter the 45-day swabbing period to be screen for the study. * Completion and collection of greater than or equal to 80% (36 days) of the 45-day consecutive daily genital swabs. Exclusion Criteria: * Severe active infection, compromised cardiopulmonary function, or other serious medical illness that, in the opinion of the principal investigator, would prevent study completion. * A history of herpes simplex virus (HSV) infection of the eye (herpes simplex interstitial keratitis or uveitis), or herpes-associated erythema multiforme. * A history of immune suppression or autoimmune disorder. * Continued use of suppressive anti-viral therapy for HSV-2; a 1 week washout of any anti-viral therapy (suppressive and episodic) is required prior to initiating the swabbing period. * Concomitant use of systemic corticosteroids or immune-suppressive medications. The use of nasal steroids is …